262 related articles for article (PubMed ID: 23832706)
1. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy.
Juhlin K; Ye X; Star K; Norén GN
Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706
[TBL] [Abstract][Full Text] [Related]
2. An experimental investigation of masking in the US FDA adverse event reporting system database.
Wang HW; Hochberg AM; Pearson RK; Hauben M
Drug Saf; 2010 Dec; 33(12):1117-33. PubMed ID: 21077702
[TBL] [Abstract][Full Text] [Related]
3. Assessing the extent and impact of the masking effect of disproportionality analyses on two spontaneous reporting systems databases.
Maignen F; Hauben M; Hung E; Van Holle L; Dogne JM
Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):195-207. PubMed ID: 24243665
[TBL] [Abstract][Full Text] [Related]
4. A conceptual approach to the masking effect of measures of disproportionality.
Maignen F; Hauben M; Hung E; Holle LV; Dogne JM
Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):208-17. PubMed ID: 24243699
[TBL] [Abstract][Full Text] [Related]
5. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database.
Kumlien E; Lundberg PO
Seizure; 2010 Mar; 19(2):69-73. PubMed ID: 20036167
[TBL] [Abstract][Full Text] [Related]
6. Postmarketing hepatic adverse event experience with PEGylated/non-PEGylated drugs: a disproportionality analysis.
Hauben M; Vegni F; Reich L; Younus M
Eur J Gastroenterol Hepatol; 2007 Nov; 19(11):934-41. PubMed ID: 18049161
[TBL] [Abstract][Full Text] [Related]
7. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase.
Strandell J; Caster O; Bate A; Norén N; Edwards IR
Drug Saf; 2011 Mar; 34(3):253-66. PubMed ID: 21332249
[TBL] [Abstract][Full Text] [Related]
8. Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection.
de Bie S; Verhamme KM; Straus SM; Stricker BH; Sturkenboom MC
Drug Saf; 2012 Apr; 35(4):335-46. PubMed ID: 22435344
[TBL] [Abstract][Full Text] [Related]
9. A Method for the Minimization of Competition Bias in Signal Detection from Spontaneous Reporting Databases.
Arnaud M; Salvo F; Ahmed I; Robinson P; Moore N; Bégaud B; Tubert-Bitter P; Pariente A
Drug Saf; 2016 Mar; 39(3):251-60. PubMed ID: 26715499
[TBL] [Abstract][Full Text] [Related]
10. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
[TBL] [Abstract][Full Text] [Related]
11. Disease-related adverse events following non-live vaccines: investigation of a newly described reporting bias through the analysis of the WHO Global ICSR Database, VigiBase.
Roberto G; Zanoni G
Vaccine; 2014 May; 32(26):3328-35. PubMed ID: 24291198
[TBL] [Abstract][Full Text] [Related]
12. Detection of adverse drug reactions using hospital databases-a nationwide study in Portugal.
Miguel A; Bernardo Marques ; Freitas A; Lopes F; Azevedo L; Pereira AC
Pharmacoepidemiol Drug Saf; 2013 Aug; 22(8):907-13. PubMed ID: 23761351
[TBL] [Abstract][Full Text] [Related]
13. Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Giezen TJ; Mantel-Teeuwisse AK; Meyboom RH; Straus SM; Leufkens HG; Egberts TC
Drug Saf; 2010 Oct; 33(10):865-78. PubMed ID: 20812771
[TBL] [Abstract][Full Text] [Related]
14. Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases.
Avillach P; Salvo F; Thiessard F; Miremont-Salamé G; Fourrier-Reglat A; Haramburu F; Bégaud B; Moore N; Pariente A;
Pharmacoepidemiol Drug Saf; 2014 Feb; 23(2):186-94. PubMed ID: 23670805
[TBL] [Abstract][Full Text] [Related]
15. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from VigiBase, the WHO global database of individual case safety reports.
Conte C; Rousseau V; Vert C; Montastruc F; Montastruc JL; Durrieu G; Olivier P
Fundam Clin Pharmacol; 2020 Aug; 34(4):518-520. PubMed ID: 32022302
[TBL] [Abstract][Full Text] [Related]
16. How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme.
Hazell L; Cornelius V; Hannaford P; Shakir S; Avery AJ;
Drug Saf; 2013 Mar; 36(3):199-206. PubMed ID: 23444232
[TBL] [Abstract][Full Text] [Related]
17. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
18. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China.
Hou Y; Ye X; Wu G; Cheng G; Du X; He J
Expert Opin Drug Saf; 2014 Jul; 13(7):853-7. PubMed ID: 24918197
[TBL] [Abstract][Full Text] [Related]
19. Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from VigiBase®.
Pokladnikova J; Meyboom RH; Meincke R; Niedrig D; Russmann S
Drug Saf; 2016 May; 39(5):455-64. PubMed ID: 26936182
[TBL] [Abstract][Full Text] [Related]
20. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
Svendsen K; Wood M; Olsson E; Nordeng H
Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
